Європейський Союз - ісландська - EMA (European Medicines Agency)

mylan pharmaceuticals limited - zonisamíðs - flogaveiki - antiepileptics, - sér í meðferð hluta flog, með eða án efri almenn ákvörðun er tekin, í fullorðnir með nýlega greind flogaveiki;venjulega meðferð í meðferð hluta flog, með eða án efri almenn ákvörðun er tekin, í fullorðnir, unglingar, og börn sem eru 6 ára og eldri.

Європейський Союз - ісландська - EMA (European Medicines Agency)

dompe farmaceutici s.p.a. - recombinant human nerve growth factor - keratitis - augnlækningar - meðferð við miðlungsmiklum (viðvarandi þekjuvef) eða alvarlega (hornhimnusár) taugakvilla í fullorðnum hjá fullorðnum.

Європейський Союз - ісландська - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - adalimumab - hidradenitis suppurativa; arthritis, psoriatic; psoriasis; crohn disease; arthritis, juvenile rheumatoid; uveitis; arthritis, rheumatoid; colitis, ulcerative; spondylitis, ankylosing - Ónæmisbælandi lyf - vinsamlegast skoðaðu kafla 4. 1 af samantekt á eiginleikum vöru í upplýsingaskjalinu.

Європейський Союз - ісландська - EMA (European Medicines Agency)

samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - augnlækningar - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Європейський Союз - ісландська - EMA (European Medicines Agency)

stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - augnlækningar - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Європейський Союз - ісландська - EMA (European Medicines Agency)

midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - augnlækningar - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).

Ісландія - ісландська - LYFJASTOFNUN (Icelandic Medicines Agency)

santen oy* - tafluprostum inn; timololum maleat - augndropar, lausn - 15 microg/ml + 5 mg/ml

Ісландія - ісландська - LYFJASTOFNUN (Icelandic Medicines Agency)

lyfjaver ehf. - aripiprazolum inn - stungulyfsstofn og leysir, forðadreifa - 400 mg

Ісландія - ісландська - LYFJASTOFNUN (Icelandic Medicines Agency)

t.p. whelehan son & co. ltd. - buserelinum acetat - stungulyf, lausn - 0,004 mg/ml

Ісландія - ісландська - LYFJASTOFNUN (Icelandic Medicines Agency)

pfizer aps - somatropinum inn - stungulyfsstofn og leysir, lausn - 12 mg